Nautilus Biotechnology (NAUT) to Release Earnings on Thursday

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nautilus Biotechnology Stock Down 0.4%

Nautilus Biotechnology stock traded down $0.00 during midday trading on Friday, hitting $0.76. The company's stock had a trading volume of 79,442 shares, compared to its average volume of 454,327. The stock's 50-day moving average price is $0.75 and its 200-day moving average price is $1.05. Nautilus Biotechnology has a 12 month low of $0.66 and a 12 month high of $3.09. The company has a market capitalization of $95.61 million, a PE ratio of -1.40 and a beta of 1.42.

Institutional Investors Weigh In On Nautilus Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in Nautilus Biotechnology by 37.1% during the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company's stock worth $83,000 after buying an additional 13,363 shares during the period. Acadian Asset Management LLC raised its holdings in Nautilus Biotechnology by 468.3% during the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company's stock worth $51,000 after buying an additional 50,871 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Nautilus Biotechnology during the 1st quarter worth about $194,000. 50.71% of the stock is currently owned by institutional investors.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.